Lates News

As of Friday's closing, Kailera Therapeutics soared 62.5% on its first day of trading, reaching a market value of $3 billion. The company, founded in 2024, is developing four GLP-1-based weight-loss drugs, including an GLP-1/GIP dual receptor agonist injection HRS9531 licensed from Chinese partner Hengrui Medicine. The prospectus shows that Bain Capital and Hengrui Medicine are both shareholders with more than 5% stake in Kailera.